Literature DB >> 26762749

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment.

Jun Soo Ham1, Seokhwi Kim2, Hee Kyung Kim1, Seonggyu Byeon1, Jong-Mu Sun1, Se-Hoon Lee1, Jin Seok Ahn1, Keunchil Park1, Yoon-La Choi2, Joungho Han2, Woongyang Park3, Myung-Ju Ahn4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26762749     DOI： 10.1016/j.jtho.2015.09.013

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  40 in total

1.  Small-cell lung carcinoma transformation of lung adenocarcinoma diagnosed by pericardial effusion: A case report.

Authors:  Ryota Otoshi; Akimasa Sekine; Koji Okudela; Masato Asaoka; Yozo Sato; Satoshi Ikeda; Tomohisa Baba; Shigeru Komatsu; Eri Hagiwara; Takashi Ogura
Journal:  Mol Clin Oncol       Date:  2020-06-03

Review 2.  Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

Authors:  Roberta Minari; Paola Bordi; Marcello Tiseo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 3.  Lung cancer as a paradigm for precision oncology in solid tumours.

Authors:  Simon Schallenberg; Sabine Merkelbach-Bruse; Reinhard Buettner
Journal:  Virchows Arch       Date:  2017-07-20       Impact factor: 4.064

4.  Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI.

Authors:  Yusuke Okuma; Yukio Hosomi
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 5.  Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.

Authors:  Joan Rou-En Choo; Chee-Seng Tan; Ross A Soo
Journal:  Target Oncol       Date:  2018-04       Impact factor: 4.493

Review 6.  Overcoming therapy resistance in EGFR-mutant lung cancer.

Authors:  Pasi A Jänne; Tony Mok; Solange Peters; Antonio Passaro
Journal:  Nat Cancer       Date:  2021-04-15

7.  Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.

Authors:  Shuxiang Ma; Zhen He; Hongyong Fu; Lili Wang; Xuan Wu; Zhe Zhang; Qiming Wang
Journal:  Transl Lung Cancer Res       Date:  2020-02

8.  Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines.

Authors:  Jordi Codony-Servat; Santiago Viteri; Carles Codony-Servat; Masaoki Ito; Jillian Willhelmina Paulina Bracht; Jordi Berenguer; Imane Chaib; Miguel Angel Molina-Vila; Niki Karachaliou; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2019-08

9.  Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.

Authors:  Anna Buder; Ellen Heitzer; Julie Waldispühl-Geigl; Sabrina Weber; Tina Moser; Maximilian J Hochmair; Klaus Hackner; Peter Errhalt; Ulrike Setinek; Martin Filipits
Journal:  Biomolecules       Date:  2021-04-21

Review 10.  Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.

Authors:  Emma-Anne Karlsen; Sam Kahler; Joan Tefay; Shannon R Joseph; Fiona Simpson
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.